279 related articles for article (PubMed ID: 16249569)
1. Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to Janka.
Raskin P
Diabetes Care; 2005 Nov; 28(11):2811. PubMed ID: 16249569
[No Abstract] [Full Text] [Related]
2. Is basal insulin always the first choice for initiation of insulin therapy in type 2 diabetic patients?
Mannucci E; Monami M; Masotti G; Marchionni N
Exp Clin Endocrinol Diabetes; 2007 May; 115(5):339-40. PubMed ID: 17516300
[No Abstract] [Full Text] [Related]
3. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
[TBL] [Abstract][Full Text] [Related]
4. [American Diabetes Association's Annual Meeting: new data on insulin glargine: early combination promises more success].
MMW Fortschr Med; 2005 Aug; 147(33-34):44-5. PubMed ID: 16138636
[No Abstract] [Full Text] [Related]
5. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Yoshihara T; Kumashiro N; Kanazawa Y; Mita T; Sakurai Y; Kawai J; Abe M; Motojima K; Hara K; Yamazaki Y; Kanazawa A; Miwa S; Sato F; Kanno R; Shimizu T; Sakai K; Uchino H; Watada H; Tanaka Y; Kawamori R; Hirose T
Endocr J; 2006 Feb; 53(1):67-72. PubMed ID: 16543674
[TBL] [Abstract][Full Text] [Related]
7. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
8. [Intensified insulin therapy of type 2 diabetes mellitus: pre- or postprandial injection of aspart insulin?].
Jungmann E
Dtsch Med Wochenschr; 2005 May; 130(20):1254-7. PubMed ID: 15889321
[TBL] [Abstract][Full Text] [Related]
9. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
10. [Start of insulin therapy. How to ensure patient compliance?].
MMW Fortschr Med; 2006 Aug; 148(35-36):12-3. PubMed ID: 16995354
[No Abstract] [Full Text] [Related]
11. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
[TBL] [Abstract][Full Text] [Related]
12. Starting insulin therapy in type 2 diabetes: lesson 1.
McCall AL
Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
[No Abstract] [Full Text] [Related]
13. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
Hanefeld M; Koehler C; Hoffmann C; Wilhelm K; Kamke W; Gerstein H
Diabet Med; 2010 Feb; 27(2):175-80. PubMed ID: 20546261
[TBL] [Abstract][Full Text] [Related]
14. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
15. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function.
Mayfield JA; White RD
Am Fam Physician; 2004 Aug; 70(3):489-500. PubMed ID: 15317436
[TBL] [Abstract][Full Text] [Related]
16. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
[TBL] [Abstract][Full Text] [Related]
17. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
18. Insulin therapy for type 2 diabetes: making it work.
Dushay J; Abrahamson MJ
J Fam Pract; 2010 Apr; 59(4):E1-8. PubMed ID: 20398575
[No Abstract] [Full Text] [Related]
19. Comparison of fasting capillary glucose variability between insulin glargine and NPH.
Mu P; Lu H; Zhang G; Chen Y; Fu J; Wang M; Shu J; Zeng L
Diabetes Res Clin Pract; 2011 Jan; 91(1):e4-7. PubMed ID: 20970870
[TBL] [Abstract][Full Text] [Related]
20. [Advantages of fast-acting insulin analogs: preprandial greater HbA1c lowering -- postprandial lower weight].
MMW Fortschr Med; 2005 Aug; 147(33-34):45. PubMed ID: 16138637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
